Long-Term Open-Label Extension Study of Oral Levosimendan
Trial details
- Registry ID
- NCT07436689
- Drugs studied
- TNX-103
TrialRedline tracks 6 clinical trials sponsored by Tenax Therapeutics, Inc.: 3 Phase 3, 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Long-Term Open-Label Extension Study of Oral LevosimendanNCT07436689 | TNX-103 | Enrolling by invitation | 2029-03Estimated |
| LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2NCT07288398 | TNX-103 | Active not recruiting | 2028-06-30Estimated |
| LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEFNCT05983250 | TNX-103 | Active not recruiting | 2026-06-30Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Open-Label Rollover Study of Levosimendan in PH-HFpEF PatientsNCT03624010 | Levosimendan | Completed | 2023-04-25Actual |
| Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEFNCT03541603 | Levosimendan | Completed | 2020-04-07Actual |
| Study of Oxycyte in Severe Closed Head InjuryNCT00174980 | Oxycyte | Terminated | 2008-03Actual |
Names as written in the registry records.
NCT07288398 · Tenax Therapeutics, Inc.
Before: Recruiting. After: Active not recruiting.
NCT05983250 · Tenax Therapeutics, Inc.
Before: 16 Jun 2026. After: 30 Jun 2026.
NCT05983250 · Tenax Therapeutics, Inc.
Before: Estimated. After: Actual.
Before: Oct 2026. After: 16 Jun 2026.
Before: Recruiting. After: Active not recruiting.
NCT00174980 · Tenax Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Increase in Brain Oxygen Tension levels in severe traumatic head injury patients with GCS score of 3-9. After: Measure: Brain Dialysate Concentration Data.
Before: Jan 2008. After: Mar 2008.
Before: Completed. After: Terminated.
NCT03624010 · Tenax Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Clinical Safety measured by number of adverse events (AEs ). After: Measure: Clinical Safety.
Before: 20 participants (actual). After: 35 participants (actual).
Before: 1 Feb 2024. After: 25 Apr 2023.